Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4444-4454

  Kwatra, Deep ^a   Venugopal, Anand ^a   Standing, David ^a,b   Ponnurangam, Sivapriya ^a   Dhar, Animesh ^a,b   Mitra, Ashim ^c   Anant, Shrikant ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

ABC transporters; colon cancer; drug interaction; drug interactions; drug resistance; drug transport; drug food interaction; efflux pumps; efflux transporters; PXR

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MOMORDICA CHARANTIA EXTRACT; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PREGNANE X RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ABC TRANSPORTERS; COLON CANCER; DRUG INTERACTION; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG TRANSPORT; DRUG-FOOD INTERACTION; EFFLUX PUMPS; EFFLUX TRANSPORTERS; PXR;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CUCURBITACEAE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; PLANT EXTRACTS;

EID: 84888201758     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23753     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A,. 2012. Cancer statistics, 2012. CA Cancer J Clin 62 (1): 10-29.
2. Goel A, Aggarwal BB,. 2010. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62 (7): 919-930.
3. Wilken R, Veena MS, Wang MB, Srivatsan ES,. 2011. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10: 12.
4. Yin J, Zhang H, Ye J,. 2008. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 8 (2): 99-111.
5. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ,. 2007. Dietary polyphenolic phytochemicals-Promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 120 (3): 451-458.
6. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S,. 2009. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br J Nutr 102 (12): 1703-1708.
7. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR,. 2008. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 100 (4): 751-759.
8. Nerurkar P, Ray RB,. 2010. Bitter melon: Antagonist to cancer. Pharm Res 27 (6): 1049-1053.
9. Basch E, Gabardi S, Ulbricht C,. 2003. Bitter melon (Momordica charantia): A review of efficacy and safety. Am J Health Syst Pharm 60 (4): 356-359.
10. Kwatra D, Subramaniam D, Ramamoorthy P, Standing D, Moran E, Velayutham R, Mitra A, Umar S, Anant S,. 2013. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid Based Complem Altern Med 2013: 702869.
11. Ray RB, Raychoudhuri A, Steele R, Nerurkar P,. 2010. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70 (5): 1925-1931.
12. Nagasawa H, Watanabe K, Inatomi H,. 2002. Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med 30 (2-3): 195-205.
13. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB,. 2011. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila) 4 (12): 2122-2130.
14. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH,. 2006. Carcinogen and anticancer drug transport by Mrp2 in vivo: Studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318 (1): 319-327.
15. Szaflarski W, Sujka-Kordowska P, Januchowski R, Wojtowicz K, Andrzejewska M, Nowicki M, Zabel M,. 2013. Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Biomed Pharmacother Biomed Pharmacother 67 (6): 497-502.
16. Kuang YH, Patel JP, Sodani K, Wu CP, Liao LQ, Patel A, Tiwari AK, Dai CL, Chen X, Fu LW, Ambudkar SV, Korlipara VL, Chen ZS,. 2012. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol 84 (6): 766-774.
17. Gottesman MM, Fojo T, Bates SE,. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2 (1): 48-58.
18. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I,. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84 (1): 265-269.
19. Gatmaitan ZC, Arias IM,. 1993. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24: 77-97.
20. Borst P,. 2012. Cancer drug pan-resistance: Pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biology 2 (5): 120066.
21. Treasure J,. 2005. Herbal medicine and cancer: An introductory overview. Semin Oncol Nurs 21 (3): 177-183.
22. Jatoi A,. 2010. Cancer chemotherapy: With or without food? Support Care Cancer 18 Suppl 2: S13-S16.
23. Singh BN, Malhotra BK,. 2004. Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43 (15): 1127-1156.
24. Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, Sakuda SH, Nagasawa H, Shimizu M,. 2004. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol 143 (3): 379-387.
25. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, Anant S,. 2008. Diphenyl difluoroketone: A curcumin derivative with potent in vivo anticancer activity. Cancer Res 68 (6): 1962-1969.
26. Kwatra D, Boddu SH, Mitra AK,. 2011. MDCK cells and other cell-culture models of oral drug absorption. Oral Bioavail: 443-459.
27. Hardie DG,. 2013. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62 (7): 2164-2172.
28. Choi YK, Park KG,. 2013. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. [Epub ahead of print.]
29. Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H, Asnafi V, Pontier-Bres R, Reverso J, Michiels JF, Sahra IB, Bost F, Peyron JF,. 2013. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett 336 (1): 114-126.
30. Wiench B, Eichhorn T, Korn B, Paulsen M, Efferth T,. 2012. Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics. Methods 57 (3): 376-382.
31. Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A,. 2012. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131 (12): 2920-2928.
32. Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA,. 2012. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol 124 (3): 575-581.
33. Luo S, Pal D, Shah SJ, Kwatra D, Paturi KD, Mitra AK,. 2010. Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Mol Pharm 7 (2): 412-420.
34. Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK,. 2010. Interaction of gatifloxacin with efflux transporters: A possible mechanism for drug resistance. Int J Pharm 395 (1-2): 114-121.
35. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D,. 2012. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83 (8): 1112-1126.
36. Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH,. 2010. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol 66 (4): 765-771.
37. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA,. 2002. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (4): 2908-2915.
38. Anapolsky A, Teng S, Dixit S, Piquette-Miller M,. 2006. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and -metabolizing enzymes in mice. Drug Metab Dispos 34 (3): 405-409.
39. Pondugula SR, Mani S,. 2013. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett 328 (1): 1-9.